logo
  

Bull & Lifshitz Announces Investigation Of Winn-Dixie Stores - Quick Facts

Bull & Lifshitz LLP announced an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Winn-Dixie Stores Inc. (WINN) to BI-LO LLC. Pursuant to the definitive agreement, BI-LO would acquire all of the outstanding shares of Winn-Dixie stock in the merger. Winn-Dixie shareholders would receive $9.50 in cash per share of Winn-Dixie common stock.

Bull & Lifshitz, LLP's investigation is focused on whether the proposed deal provides adequate value to the company's shareholders.

In addition, Bull & Lifshitz announced an investigation into possible breaches of fiduciary duty in connection with the proposed sale of Morton's Restaurants Group, Inc. (MRT) to Tilman J. Fertitta through his wholly-owned company, Fertitta's Morton's Restaurants, Inc. and its unit Fertitta Morton's Acquisition, Inc. As per the deal, Morton's stockholders would receive $6.90 for every Morton's stock owned. Fertitta would buy Morton's through an all-cash tender and merger. The tender offer would commence no later than 10 business days from December 16, 2011.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Beverages giant Coca-Cola Co. (KO) reported Tuesday a profit for the first quarter that grew 2 percent from last year, reflecting lower income taxes and a 3 percent revenue growth. Both adjusted earnings per share and quarterly revenues topped analysts' expectations. The company also maintained its adjusted earnings guidance for the full-year 2024, but raised organic revenue growth outlook. Shares of Mercedes-Benz Group AG were losing around 5 percent in the German trading after the automobile major reported Tuesday weak profit and revenues in its first quarter amid lower unit sales of cars. The company also confirmed its fiscal 2024 outlook, expecting lower earnings and flat revenues. While reporting financial results for the first quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound and greater visibility into the company's production...

This week, we feature OJEMDA’s FDA approval, Bristol Myer’s Job cuts, Novo Nordisk’s increased pricing of drugs in US, Incyte’s strategic acquisition, and Ireland’s Alcohol labels.

View More Videos
Follow RTT